Document is current
Any future updates will be listed below
-
Authors
Sendi, Mohammad S. E. https://orcid.org/0000-0003-2946-1786
Fu, Zening https://orcid.org/0000-0002-1591-4900
Harnett, Nathaniel G. https://orcid.org/0000-0001-5346-2012
van Rooij, Sanne J. H. https://orcid.org/0000-0002-0160-7248
Vergara, Victor
Pizzagalli, Diego A. https://orcid.org/0000-0002-7772-1143
Daskalakis, Nikolaos P. https://orcid.org/0000-0003-1660-9112
House, Stacey L.
Beaudoin, Francesca L.
An, Xinming
Neylan, Thomas C. https://orcid.org/0000-0002-1572-2626
Clifford, Gari D.
Jovanovic, Tanja
Linnstaedt, Sarah D. https://orcid.org/0000-0001-5295-7072
Germine, Laura T. https://orcid.org/0000-0001-8690-8412
Bollen, Kenneth A.
Rauch, Scott L.
Haran, John P. https://orcid.org/0000-0001-7311-1121
Storrow, Alan B. https://orcid.org/0000-0002-2893-808X
Lewandowski, Christopher https://orcid.org/0000-0001-8297-0024
Musey, Paul I. Jr. https://orcid.org/0000-0002-5693-190X
Hendry, Phyllis L.
Sheikh, Sophia https://orcid.org/0000-0003-1939-3126
Jones, Christopher W.
Punches, Brittany E. https://orcid.org/0000-0002-7546-1966
Swor, Robert A.
Gentile, Nina T.
Murty, Vishnu P.
Hudak, Lauren A.
Pascual, Jose L. https://orcid.org/0000-0002-1613-7912
Seamon, Mark J.
Harris, Erica
Chang, Anna M.
Pearson, Claire
Peak, David A.
Merchant, Roland C.
Domeier, Robert M.
Rathlev, Niels K.
O’Neil, Brian J.
Sergot, Paulina
Sanchez, Leon D. https://orcid.org/0000-0002-8807-0913
Bruce, Steven E. https://orcid.org/0000-0002-5807-4382
Sheridan, John F.
Harte, Steven E.
Kessler, Ronald C. https://orcid.org/0000-0003-4831-2305
Koenen, Karestan C. https://orcid.org/0000-0003-2978-7655
McLean, Samuel A. https://orcid.org/0000-0001-9482-3582
Stevens, Jennifer S. https://orcid.org/0000-0003-4674-0314
Calhoun, Vince D. https://orcid.org/0000-0001-9058-0747
Ressler, Kerry J. https://orcid.org/0000-0002-5158-1103
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (T32MH125786, K01MH129828, 1K01MH121653, R01MH129495, R01MH122867, R01MH121617, U01MH110925, R01MH123610)
- License Information
-
More Information
Article History
Received: 1 March 2024
Accepted: 5 December 2024
First Online: 20 January 2025
Competing interests
: M.S.E.S. has served as a consultant for Niji Corp for unrelated work. N.P.D. is on the scientific advisory board for Sentio Solutions, Inc. and Circular Genomics, Inc. Over the past 3 years, D.A. Pizzagalli has received consulting fees from Boehringer Ingelheim, Compass Pathways, Engrail Therapeutics, Neumora Therapeutics (former BlackThorn Therapeutics), Neurocrine Biosciences, Neuroscience Software, Otsuka Pharmaceuticals, Sage Therapeutics and Takeda Pharmaceuticals; honoraria from the Psychonomic Society and the American Psychological Association (for editorial work) and Alkermes, and research funding from the Bird Foundation, Brain and Behavior Research Foundation, DARPA, Millennium Pharmaceuticals and the National Institute of Mental Health. In addition, he has received stock options from Compass Pathways, Engrail Therapeutics, Neumora Therapeutics (former BlackThorn Therapeutics) and Neuroscience Software. T.C.N. has received research support from NIH, VA and Rainwater Charitable Foundation, and consulting income from Jazz Pharmaceuticals. In the past 3 years, G.D.C. has received research funding from the NSF, NIH and LifeBell AI, and unrestricted donations from AliveCor Inc., Amazon Research, the Center for Discovery, the Gates Foundation, Google, the Gordon and Betty Moore Foundation, MathWorks, Microsoft Research, Nextsense Inc., One Mind Foundation and the Rett Research Foundation. G.D.C. has financial interest in AliveCor Inc. and Nextsense Inc. He also is the CTO of MindChild Medical with significant stock. These relationships are unconnected to the current work. L.T.G. is on the board of the Many Brains Project. Her family also has equity in Intelerad Medical Systems, Inc. S.L.R. reported serving as secretary of the Society of Biological Psychiatry; serving as a board member of Community Psychiatry and Mindpath Health; serving as a board member of National Association of Behavioral Healthcare; serving as secretary and a board member for the Anxiety and Depression Association of America; serving as a board member of the National Network of Depression Centers; receiving royalties from Oxford University Press, American Psychiatric Publishing Inc. and Springer Publishing; and receiving personal fees from the Society of Biological Psychiatry, Community Psychiatry and Mindpath Health, and National Association of Behavioral Healthcare outside the submitted work. C.W.J. has no competing interests related to this work, although he has been an investigator on studies funded by AstraZeneca, Vapotherm, Abbott and Ophirex. S.E.H. has no competing interest related to this work, although in the past 3 years he has received research funding from Aptinyx and Arbor Medical Innovations, and consulting payments from Aptinyx. In the past 3 years, R.C.K. was a consultant for Cambridge Health Alliance, Canandaigua VA Medical Center, Holmusk, Partners Healthcare, Inc., RallyPoint Networks, Inc. and Sage Therapeutics. He has stock options in Cerebral Inc., Mirah, PYM and Roga Sciences. K.C.K.’s research has been supported by the Robert Wood Johnson Foundation, the Kaiser Family Foundation, the Harvard Center on the Developing Child, Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard, the National Institutes of Health, One Mind, the Anonymous Foundation and Cohen Veterans Bioscience. She has been a paid consultant for Baker Hostetler, Discovery Vitality and the Department of Justice. She has been a paid external reviewer for the Chan Zuckerberg Foundation, the University of Cape Town and Capita Ireland. She has had paid speaking engagements in the past 3 years with the American Psychological Association, European Central Bank. Sigmund Freud University–Milan, Cambridge Health Alliance and Coverys. She receives royalties from Guilford Press and Oxford University Press. S.A.M. has served as a consultant for Walter Reed Army Institute for Research, Arbor Medical Innovations and BioXcel Therapeutics, Inc. K.J.R. has performed scientific consultation for Bioxcel, Bionomics, Acer and Jazz Pharma; serves on scientific advisory boards for Sage, Boehringer Ingelheim, Senseye and the Brain Research Foundation; and has received sponsored research support from Alto Neuroscience. The other authors declare no competing interests.
